Parsippany, New Jersey. Edenbridge Pharmaceuticals announces the launch of its miglustat capsules 100mg.
Generic version of Zavesca®* capsules being distributed by Orsini Specialty Pharmacy and offered with a co-pay program for eligible patients.
Edenbridge Pharmaceuticals, LLC announces the launch of miglustat capsules 100mg. Edenbridge’s miglustat capsules 100mg are a generic version of Zavesca®* (miglustat capsules 100mg) and are being distributed through Orsini Specialty Pharmacy, a nationwide, independent specialty pharmacy focused on rare diseases and gene therapies. As part of its launch, Edenbridge is offering a co-pay program for eligible patients. “Our launch of miglustat in the U.S. is a significant step for Edenbridge in improving the lives of patients and families with rare diseases” notes Edenbridge’s CEO Ryan Collins.
This product launch and U.S. FDA approval follows Edenbridge’s 2017 approval by the European Medicines Agency (EMA) of the first generic version of Zavesca®* to receive approval through the centralized procedure for sale in all EMA member states.